Precigen (PGEN) Operating Margin (2012 - 2026)
Precigen (PGEN) posted quarterly Operating Margin of 25.78% for Q1 2026, up 165923.0% year-over-year from N/an in Q1 2025, and up 90.64% quarter-over-quarter from 275.44% in Q4 2025.
Precigen (PGEN) Operating Margin (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Operating Margin for 15 consecutive years, with 25.78% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 165923.0% year-over-year to 25.78%; the TTM figure through Mar 2026 stood at 285.94% (up 203125.0% YoY), while the FY2025 annual figure was 1141.13%, up 229910.0% from the prior year.
- Operating Margin grew to 25.78% in Q1 2026 per PGEN's latest filing, from 275.44% in the prior quarter.
- Across five years, Operating Margin topped out at 149.86% in Q4 2022 and bottomed at 2126200.0% in Q3 2024.
- Historically, Operating Margin has averaged 265392.52% across 5 years, with a median of 1440.13% in 2025.
- Annual changes were most pronounced in 2023 — Operating Margin tumbled 209364793 bps — and 2025, when it soared 212253960 bps.
- Precigen's Operating Margin stood at 149.86% in 2022, then slumped by 1960 bps to 2786.97% in 2023, then jumped by 72 bps to 772.79% in 2024, then soared by 64 bps to 275.44% in 2025, then jumped by 91 bps to 25.78% in 2026.
- Business Quant data shows PGEN's Operating Margin at 25.78% in Q1 2026, 275.44% in Q4 2025, and 3660.4% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 41.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.18% |
| Mar 31, 2026 | -25.78% |
| Dec 31, 2025 | -275.44% |
| Sep 30, 2025 | -3,660.40% |
| Jun 30, 2025 | -4,067.09% |
| Mar 31, 2025 | -1,685.01% |
| Dec 31, 2024 | -772.79% |
| Sep 30, 2024 | -2,126,200.00% |
| Jun 30, 2024 | -8,485.50% |
| Mar 31, 2024 | -2,292.02% |
| Dec 31, 2023 | -2,786.97% |
| Sep 30, 2023 | -2,093,700.00% |
| Jun 30, 2023 | -1,195.25% |
| Dec 31, 2022 | 149.86% |
| Sep 30, 2022 | -52.07% |
| Jun 30, 2022 | -830.02% |
| Mar 31, 2022 | -401.83% |
| Dec 31, 2021 | 217.05% |
| Sep 30, 2021 | -645.96% |
| Jun 30, 2021 | -687.18% |